YY

Yuexin Yu

Director at Andera Partners

Paris, Île-de-France

Investor
VC

Invests in

Sectors:

BioTech

Locations:

Paris, France

  • Min Investment:

    $5,000,000.00

  • Max Investment:

    $35,000,000.00

  • Target Investment:

    $20,000,000.00

Skills

Market Analysis
Financial Analysis
Strategy
Market Research
Due Diligence
Pharmaceutical Industry
Biotechnology
Medical Diagnostics
Venture Capital
Business Planning
Valuation
Finance
Management
Project Management
Business Strategy

Education

Lists including Yuexin

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Work Experience

AP
Andera Partners

2021

  • Director

    2024

    Amolyt (acquired by AstraZeneca), JenaValve (acquired by Edwards), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), Mineralys (MLYS), Artios, Evommune, Tubulis, TargED

  • Investment Director

    2021 - 2024

E
Evommune

2024

  • Board Member

    2024

JT
JenaValve Technology, Inc.

2022

  • Board Observer

    2022

TB
TargED Biopharmaceuticals

2022

  • Board Observer

    2022

3H
3H Health Investment Management

2016 - 2021

  • Vice President

    2020 - 2021

    InnoCare (HK.9969, SH.688428), KeyMed (HK.2162), CanSino (HK.6185), EdiGen, RareStone Group, Imperative Care, HeMo Bioengineering

  • Senior Associate

    2018 - 2020

  • Associate

    2016 - 2018

M
Merck

2014 - 2016

  • Project Manager

    2014 - 2016

    Remicade, Keytruda

b
bioTheranostics

2013 - 2013

  • Business Development Associate

    2013 - 2013

ME
Merieux Equity Partners

2012 - 2013

  • Business Analyst

    2012 - 2013